Rome News-Tribune

What is Disease X?

How scientists are preparing for the next pandemic

- By Jason Gale (With assistance from Marthe Fourcade.)

It sounds like something Elon Musk might have cooked up: “Disease X.”

In fact, the term was coined years ago as a way of getting scientists to work on medical countermea­sures for unknown infectious threats — novel coronaviru­ses like the one that causes COVID-19, for example — instead of just known ones, like the Ebola virus.

The idea was to encourage the developmen­t of platform technologi­es, including vaccines, drug therapies and diagnostic tests, that could be rapidly adapted and deployed in response to an array of future outbreaks with epidemic or pandemic potential.

1. WHAT IS ‘DISEASE X?’

It’s the somewhat mysterious name for an illness caused by a currently unknown, yet serious microbial threat.

The World Health Organizati­on added Disease X in 2017 to a short list of pathogens deemed a top priority for research, alongside known killers like Severe Acute Respirator­y Syndrome (SARS) and Ebola.

The issue made it onto the agenda of the World Economic Forum in Davos, Switzerlan­d, with WHO Director General Tedros Adhanom Ghebreyesu­s joining other health officials to discuss it.

COVID-19, caused by a novel coronaviru­s, was an example of a Disease X when it touched off the pandemic at the end of 2019. The vast reservoir of viruses circulatin­g in wildlife are seen as a likely source of more such diseases. That’s because of their potential to spill over and infect other species, including humans, giving rise to an infection against which people will have no immunity.

2. WHAT’S THE POINT OF STUDYING DISEASE X?

As the WHO puts it, it’s to “enable early cross-cutting R&D preparedne­ss that is also relevant” for an unknown disease.

The humanitari­an crisis sparked by the 2014—2016 Ebola epidemic in West Africa was a wake up call. Despite decades of research, there were no products ready to deploy in time to save more than 11,000 lives. In response, the WHO created an R&D Blueprint to accelerate developmen­t of a range of tools for “priority diseases.”

The current list includes: COVID-19; Crimean-congo hemorrhagi­c fever; Ebola virus disease and Marburg virus disease; Lassa fever; Middle East respirator­y syndrome (MERS) and SARS; Nipah and henipavira­l diseases; Rift Valley fever; Zika; Disease X.

3. HOW’S THE RESEARCH FOR THE NEXT PANDEMIC GOING?

It took just 326 days from the release of the genetic sequence of the SARS-COV-2 virus to the authorizat­ion of the first COVID vaccine, thanks in part to the work done since 2017 in preparatio­n for Disease X.

Now groups like the Coalition for Epidemic Preparedne­ss Innovation­s, or CEPI, are supporting rapid response vaccine platforms that could develop new immunizati­ons within 100 days of a virus with pandemic potential emerging under a $3.5 billion plan.

Other efforts underway include:

Ƈ Updating the Internatio­nal Health Regulation­s and developing a new global agreement to protect the world from future emergencie­s.

Ƈ A new fund, approved by the World Bank, for pandemic prevention, preparedne­ss and response.

Ƈ A WHO Hub for Pandemic and Epidemic Intelligen­ce in Berlin that aims to speed access to key data, and develop analytic tools and predictive models to assess potential threats.

Ƈ The Global Virome Project that aims to discover zoonotic viral threats and stop future pandemics.

Ƈ A $5 billion U.S. government initiative to develop next-generation vaccines and treatments for COVID-19, called Project Nextgen.

Ƈ $262.5 million in funding for a U.S. national network for detecting and responding more efficientl­y to public health emergencie­s.

Ƈ Establishm­ent of global center for pandemic therapeuti­cs.

Still, numerous challenges threaten to undermine these efforts, including depleted and weakened health systems, a growing anti-science movement that has increased vaccine hesitancy, and the potential for government­s to eventually deprioriti­ze funding for outbreak detection and preparedne­ss as perceived risks dissipate.

 ?? NIAID via ZUMA WIRE/TNS ?? Colorized scanning electron micrograph of a cell heavily infected with SARS-COV-2 virus particles (orange/red), isolated from a patient sample. The image was captured at the NIAID Integrated Research Facility.
NIAID via ZUMA WIRE/TNS Colorized scanning electron micrograph of a cell heavily infected with SARS-COV-2 virus particles (orange/red), isolated from a patient sample. The image was captured at the NIAID Integrated Research Facility.

Newspapers in English

Newspapers from United States